Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies

[wpbb post:title]
David Miklos, MD, PhD, Chief Clinical Director, Blood and Marrow Transplantation and Cellular Therapy, Cancer Cell Therapy Stanford University
  • CAR-T benefits are T cell dependent

  • Treatment schema for CAR-T cell therapy

  • Explore several case studies

2021-09-30T12:20:08-04:00